Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939671 | 1.00 | POLB (0.33) | POLBL3MBTL1DRD1NPSR1MCHR1 | |
| SCHEMBL22026376 | 1.00 | POLB (0.33) | POLBL3MBTL1DRD1NPSR1MCHR1 | |
| SCHEMBL30939529 | 0.89 | POLB (0.34) | POLBL3MBTL1DRD1NPSR1MCHR1 | |
| SCHEMBL1978383 | 0.89 | POLB (0.34) | POLBL3MBTL1DRD1NPSR1MCHR1 | |
| SCHEMBL1979317 | 0.88 | NPSR1 (0.38) | L3MBTL1NPSR1MCHR1 | |
| SCHEMBL30939590 | 0.88 | NPSR1 (0.38) | L3MBTL1NPSR1MCHR1 | |
| SCHEMBL13828582 | 0.85 | POLB (0.37) | POLBL3MBTL1MCHR1 | |
| SCHEMBL30939519 | 0.79 | AR (0.35) | POLBL3MBTL1DRD1 | |
| SCHEMBL1979866 | 0.79 | AR (0.35) | POLBL3MBTL1DRD1 | |
| SCHEMBL30939555 | 0.78 | AR (0.45) | POLBL3MBTL1DRD1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | claimed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | claimed |
| US-20190000848-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-01-03 | — | — | US | claimed |
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-11-29 | — | — | US | claimed |
| EP-3386506-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | Autifony Therapeutics Limited (GB) | 2018-10-17 | — | — | EP | claimed |
| US-10058551-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-08-28 | — | — | US | claimed |
| US-9849131-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | claimed |
| EP-2852588-B1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2017-11-29 | — | — | EP | claimed |
| WO-2017098254-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-15 | — | — | WO | claimed |
| US-9669030-B2 | Hydantoin derivatives as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | claimed |
| EP-2509961-B1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-09 | — | — | EP | claimed |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-03-03 | — | — | US | claimed |
| US-20150157631-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | US | claimed |
| EP-2852588-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2015-04-01 | — | — | EP | claimed |
| US-8722695-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2014-05-13 | — | — | US | claimed |
| WO-2013182851-A1 | PROPHYLAXIS OR TREATMENT OF DISEASES WHERE A MODULATOR OF KV3.3 CHANNELS IS REQUIRED | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-12-12 | — | — | WO | claimed |
| WO-2013175211-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-11-28 | — | — | WO | claimed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | claimed |
| EP-2509961-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | Autifony Therapeutics Limited (GB) | 2012-10-17 | — | — | EP | claimed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | POLB 4014/4885L3MBTL1 4332/4885DRD1 201/4885 |
| US-20190000848-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | POLB 4505/4885L3MBTL1 3475/4885DRD1 2203/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | POLB 4014/4885L3MBTL1 4332/4885DRD1 201/4885 |
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | POLB 4014/4885L3MBTL1 4332/4885DRD1 201/4885 |
| US-10058551-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | POLB 4014/4885L3MBTL1 4332/4885DRD1 201/4885 |
| US-20150157631-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | KCND3, KCNA3, KCNK3 | POLB 4349/4885L3MBTL1 1445/4885DRD1 4117/4885 |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | POLB 4010/4885L3MBTL1 4300/4885DRD1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.